Save 20% on your order with code
K4 Elite logo K4 Elite
Home / Research Trials / CJC-1295 / Ipamorelin blend
Blend — no combined trials

CJC-1295 / Ipamorelin blend

Growth Hormone Secretagogue

No controlled clinical study of CJC-1295 and ipamorelin administered together has been published; a search of the indexed literature for the two names returns only narrative reviews and anti-doping papers. Each component has separate human data: CJC-1295 (a GHRH(1-29) analogue with albumin binding) was studied in two randomized, placebo-controlled ascending-dose trials in healthy adults (Teichman 2006), and ipamorelin (a ghrelin-receptor agonist pentapeptide) in a healthy-volunteer PK/PD infusion study (Gobburu 1999) and a phase 2 postoperative-ileus trial (Beck 2014). The individual component entries should be consulted for those data; nothing here describes the combination.

No combined trials1 reported adverse effect0 documented interactions6 references
🔬 Research use only — not for human or veterinary use. The regimens below are records of what published studies administered to their own subjects; they are not instructions and K4 Elite does not provide dosing instructions.
Published trial usage Adverse effects Interactions Contraindications References
Published trial usage

No controlled studies of this combination exist

No randomised, controlled or otherwise comparative study of this multi-component preparation as a combination has been published, in humans or in animals. There is therefore no trial regimen, no combined safety dataset and no interaction dataset to report for the blend itself.

What has been published concerns the individual components, each of which has its own record:

CJC-1295Human (small/observational)IpamorelinHuman (small/observational)
Reported adverse effects

Effects recorded in the cited reports. Frequencies are those the source reported, in the population that source studied.

EffectFrequency / contextSource
CJC-1295 (component only): no serious adverse reactions In two randomized, placebo-controlled ascending-dose trials in healthy adults aged 21-61, no serious adverse reactions were reported; the drug was described as relatively well tolerated at 30 or 60 mcg/kg (Teichman 2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults ↗
Interactions

No interactions with a verifiable citation have been indexed for this compound.

Contraindications noted in trials

No contraindications with a verifiable citation have been indexed for this compound.

References
  1. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults, J Clin Endocrinol Metab 2006
  2. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295, J Clin Endocrinol Metab 2006
  3. Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol 1998
  4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers, Pharm Res 1999
  5. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus, Int J Colorectal Dis 2014
  6. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation, Drug Test Anal 2010
Elsewhere on K4 Elite
CJC-1295 + Ipamorelin (GH Blend) — product pageAll indexed compounds — Research Trials
Research use only. This record summarises published literature for reference. It is not medical advice, not a protocol, and not a recommendation to administer this compound to any subject. Regimens are reported as the historical record of how a cited study was conducted; findings are reported without interpretation and constitute no claim of safety or efficacy. Determining any research procedure is the sole responsibility of the qualified researcher. Products referenced on this site are supplied strictly for in-vitro laboratory and research purposes, are not for diagnostic or therapeutic use, and have not been evaluated by the FDA.